CMS-1LI-22-001: Money Follows the Person Demonstration Program
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Center for Medicare and Medicaid Services notices from 2022.
Center for Medicare and Medicaid Services offered grants of up to $5.0 million to state and local governments. It expected to make about 22 awards worth $110 million in total. Applications closed on May 31, 2022.
From the official notice on Grants.gov, last changed March 31, 2022. Checked November 7, 2026.
- Award ceiling$5.0 million
- Total funding$110 million
- Expected awards22
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 31, 2022 |
|---|---|
| Deadline | May 31, 2022 |
| Archived by Grants.gov | June 30, 2022 |
Who can apply
This opportunity was open to state and local governments.
- State governments
Any single state Medicaid agency not currently participating in the MFP demonstration project may apply. By “state,” we refer to the definition provided under 45 CFR §74.2 as “any of the several States of the United States, the District of Columbia, the Commonwealth of Puerto Rico, any territory or possession of the United States, or any agency or instrumentality of a State exclusive of local governments.” By “territory or possession,” we mean Guam, the U.S. Virgin Islands, American Samoa, and the Commonwealth of the Northern Mariana Islands. Only one application can be submitted for a given state.
Is this a realistic fit?
- Past Money Follows the Person Rebalancing Demonstration awards averaged $50.8 million; this notice allows up to $5.0 million per award.
- Most of the program's money (98% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The Money Follows the Person (MFP) Demonstration, originally authorized under section 6071 of the Deficit Reduction Act of 2005 (DRA), supports state strategies to rebalance long-term services and supports (LTSS) systems from institutional to community-based care. MFP has played a key role in many states’ LTSS rebalancing efforts under the Medicaid program providing flexible funding opportunities to help states develop and test the necessary processes, tools, and infrastructure to advance LTSS system reform and to support successful transitions from institutional to community-based settings for individuals eligible for Medicaid LTSS. Under the Consolidated Appropriations Act of 2021 (CAA), Congress authorized an additional $1.253 billion in federal funds for the MFP Demonstration and extended the project through federal fiscal year (FY) 2023. The CAA also provided the Centers for Medicare & Medicaid Services (CMS) with authorization to expand the MFP Demonstration to additional states and territories. Currently, there are thirty-four (34) states, including the District of Columbia, participating in the MFP Demonstration. The MFP Demonstration Expansion focuses on states and territories not currently participating in the MFP Demonstration. The MFP Demonstration Expansion (MFP Expansion) citation in this notice of funding opportunity references states and territories eligible to apply. The Money Follows the Person Demonstration (MFP) refers to existing and new participating projects. This Notice of Funding Opportunity (NOFO) will make funds available for a Planning Phase with an anticipated start date of September 1, 2022. Award recipients will begin with the Planning Phase during which they will work with stakeholders to design and develop an MFP Demonstration that supports the states’ unique LTSS system reform goals. Award recipients will also have the opportunity to implement capacity building initiatives during and after the end of the Planning Phase. Funding requests are available for planning and capacity building for an amount up to $5 million per state; awards are anticipated to range between $4 million and $5 million per state. Funding will be available for the year in which it is awarded and four additional years.
Who has won Money Follows the Person Rebalancing Demonstration grants before
From fiscal 2021 to 2025, Money Follows the Person Rebalancing Demonstration (93.791) awarded $2.2 billion across 44 grant awards, an average of $50.8 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Department of Social & Health Services | Washington | 1 | $296 million |
| The Commonwealth of Massachusetts | Massachusetts | 1 | $176 million |
| NYS Department of Health | New York | 1 | $174 million |
| Minnesota Department of Human Services | Minnesota | 1 | $165 million |
| California Department of Health Care Services | California | 1 | $142 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CMS-1LI-22-001 still open?
No. It closed on May 31, 2022.
Who can apply for Money Follows the Person Demonstration Program?
Center for Medicare and Medicaid Services accepted applications from state and local governments. The notice adds further conditions, so read its eligibility section.
What is the deadline for Money Follows the Person Demonstration Program?
Closed May 31, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $5.0 million each. About $110 million in total across about 22 awards.
Who has won Money Follows the Person Rebalancing Demonstration grants before?
The largest recipients over five fiscal years were Department of Social & Health Services, The Commonwealth of Massachusetts, NYS Department of Health. The program made 44 awards worth $2.2 billion in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)